SG47948A1 - Compounds for the treatment of neurodegenerative disorders - Google Patents

Compounds for the treatment of neurodegenerative disorders

Info

Publication number
SG47948A1
SG47948A1 SG1996005610A SG1996005610A SG47948A1 SG 47948 A1 SG47948 A1 SG 47948A1 SG 1996005610 A SG1996005610 A SG 1996005610A SG 1996005610 A SG1996005610 A SG 1996005610A SG 47948 A1 SG47948 A1 SG 47948A1
Authority
SG
Singapore
Prior art keywords
treatment
neurodegenerative disorders
compounds
pyridineethanamine
alpha
Prior art date
Application number
SG1996005610A
Other languages
English (en)
Inventor
Michael Balestra
Ronald Conrad Griffith
Robert John Murray
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929207339A external-priority patent/GB9207339D0/en
Priority claimed from GB929208290A external-priority patent/GB9208290D0/en
Application filed by Astra Ab filed Critical Astra Ab
Publication of SG47948A1 publication Critical patent/SG47948A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
SG1996005610A 1992-04-03 1993-04-01 Compounds for the treatment of neurodegenerative disorders SG47948A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929207339A GB9207339D0 (en) 1992-04-03 1992-04-03 Pharmaceutical compound
GB929208290A GB9208290D0 (en) 1992-04-15 1992-04-15 Pharmaceutical compound having neuroprotective properties

Publications (1)

Publication Number Publication Date
SG47948A1 true SG47948A1 (en) 1998-04-17

Family

ID=26300643

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1996005610A SG47948A1 (en) 1992-04-03 1993-04-01 Compounds for the treatment of neurodegenerative disorders

Country Status (29)

Country Link
EP (1) EP0633879B1 (da)
JP (2) JP3120810B2 (da)
KR (1) KR100259567B1 (da)
CN (1) CN1044367C (da)
AT (1) ATE163925T1 (da)
AU (2) AU3897693A (da)
CA (1) CA2133427C (da)
CZ (1) CZ288519B6 (da)
DE (1) DE69317411T2 (da)
DK (1) DK0633879T3 (da)
DZ (1) DZ1677A1 (da)
ES (1) ES2115055T3 (da)
FI (1) FI105025B (da)
HK (1) HK1009331A1 (da)
HU (1) HU211529A9 (da)
IL (1) IL105276A (da)
MA (1) MA22866A1 (da)
MX (1) MX9301935A (da)
MY (1) MY110149A (da)
NO (1) NO302170B1 (da)
NZ (1) NZ251384A (da)
PL (1) PL180014B1 (da)
RU (1) RU2128650C1 (da)
SG (1) SG47948A1 (da)
SK (1) SK281258B6 (da)
TW (1) TW282455B (da)
UA (1) UA29437C2 (da)
WO (1) WO1993020052A1 (da)
ZA (1) ZA932415B (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9320273D0 (en) * 1993-04-01 1993-11-17 Fisons Corp Compound useful in therapy
SG52662A1 (en) * 1988-08-12 1998-09-28 Astra Ab Arylkalkyl-amines and -amides having anticonvulsant and neuroprotective properties
ZA942140B (en) * 1993-04-01 1994-10-03 Fisons Corp Salt of (S)-alpha-phenyl-2-pyridineethanamine useful in therapy
SE9901077D0 (sv) * 1999-03-23 1999-03-23 Astra Ab Novel use
SE9901237D0 (sv) * 1999-04-06 1999-04-06 Astra Ab Novel use
SE9901340D0 (sv) 1999-04-15 1999-04-15 Astra Pharma Prod Novel process
WO2007017652A2 (en) * 2005-08-10 2007-02-15 Astrazeneca Ab Arylakylamines for the treatment of cancer
NZ593282A (en) * 2008-12-24 2013-06-28 Astrazeneca Ab Ethanamine compounds and their use for treating depression
JP2015501652A (ja) 2011-12-14 2015-01-19 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ Ｇａｂｒ−ａ２診断
JP6479834B2 (ja) * 2013-11-05 2019-03-06 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ Ｎｍｄａアンタゴニストプロドラッグ
MX2022016183A (es) * 2020-06-23 2023-02-13 Biohaven Therapeutics Ltd Formulaciones topicas de (1s)-1-fenil-2-piridin-2-iletanamina.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG52662A1 (en) * 1988-08-12 1998-09-28 Astra Ab Arylkalkyl-amines and -amides having anticonvulsant and neuroprotective properties

Also Published As

Publication number Publication date
JP3120810B2 (ja) 2000-12-25
AU705419B2 (en) 1999-05-20
UA29437C2 (uk) 2000-11-15
AU3897693A (en) 1993-11-08
NO943645D0 (no) 1994-09-30
ES2115055T3 (es) 1998-06-16
IL105276A (en) 1997-06-10
IL105276A0 (en) 1993-08-18
NZ251384A (en) 1996-10-28
CN1044367C (zh) 1999-07-28
JPH07505385A (ja) 1995-06-15
ZA932415B (en) 1993-10-22
EP0633879A1 (en) 1995-01-18
KR100259567B1 (ko) 2000-07-01
DE69317411T2 (de) 1998-07-30
WO1993020052A1 (en) 1993-10-14
HU211529A9 (en) 1995-11-28
EP0633879B1 (en) 1998-03-11
FI944546A (fi) 1994-09-30
CN1081669A (zh) 1994-02-09
MX9301935A (es) 1994-08-31
SK117794A3 (en) 1995-05-10
RU2128650C1 (ru) 1999-04-10
RU94042465A (ru) 1996-07-20
CZ240994A3 (en) 1995-12-13
CZ288519B6 (cs) 2001-07-11
DZ1677A1 (fr) 2002-02-17
ATE163925T1 (de) 1998-03-15
AU7545696A (en) 1997-02-13
FI944546A0 (fi) 1994-09-30
HK1009331A1 (en) 1999-05-28
CA2133427C (en) 2003-06-10
TW282455B (da) 1996-08-01
DE69317411D1 (de) 1998-04-16
CA2133427A1 (en) 1993-10-14
DK0633879T3 (da) 1998-09-28
FI105025B (fi) 2000-05-31
MA22866A1 (fr) 1993-12-31
MY110149A (en) 1998-02-28
NO302170B1 (no) 1998-02-02
PL180014B1 (pl) 2000-11-30
NO943645L (no) 1994-11-16
SK281258B6 (sk) 2001-01-18
JP2000319259A (ja) 2000-11-21

Similar Documents

Publication Publication Date Title
BG102999A (en) New 2,3-diasubstituted-4-(3h)-quinazolinons
AU610036B2 (en) Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis inflammation and as immunosuppressants
IL110204A0 (en) Novel indolene derivatives, processes for their preparation and their use for the treatment of cns disorders
WO1993000094A3 (en) Use of tetrahydrobenzazepine derivatives for the treatment of portal hypertension and migraine
ZA928158B (en) Cytotoxic bicyclo[7.3.1]tridec-4-ene-2,6-diyne compounds and process for the preparation thereof.
ZA932415B (en) Compounds for the treatment of neurodegenerative disorders
EP0626162A3 (de) Krankenbett.
CA2135709A1 (en) Melatonin derivatives for use in treating sleep disorders
ZA933151B (en) Cycloheptimidazole derivatives, method of manufacturing the same and therapeutic agents containing these compounds.
HRP931016A2 (en) Thienothiazin derivatives, process for the preparation and application thereof
ZA935154B (en) Use of 1,2,5-oxadiazole-2-oxides for the treatment of erectile dysfunctions
AU6581294A (en) Ethanolamine derivatives useful for the treatment of gastrointestinal disorders
ZA949347B (en) 1,4,7,10-tetraazacyclododecane derivatives, their use, pharmaceutical agents containing these compounds and process for their production.
AU3084992A (en) 1,4-dihydropyridines for use in the treatment of dermatosis
AU4825993A (en) New compounds for use in the treatment of cancer
GB2270313B (en) 1,3,4-Benzotriazepin-5 (4H)-one derivatives and process for the preparation thereof
HK1001395A1 (en) 6-methoxy-1h-benzotriazole-5-carboxamide derivatives, process for producing the same, and medicinal composition containing the same
AU7183298A (en) Melatonin derivatives for use in treating desynchronization disorders
GR920100423A (el) Ανταγωνιστές 5-ΗΤ4 κινολιζιδινυλ εστέρος.
ZA934785B (en) 17-halogeno-4-azaandrostene derivatives and process for the preparation thereof.
ES1023651Y (es) "barandilla de cama, perfeccionada"
ZA932062B (en) Indole and indazole derivatives, for the treatment and prophylaxis of cerabral disorders, their preparation and their use
IL100396A0 (en) Medicaments for the treatment of irradiation damages
HUP9603287A3 (en) Pharmaceutical composition, use thereof and process for producing the active component
ZA925373B (en) Anti-glaucomatous pharmaceutical compositions and the process for obtaining them.